A RANDOMIZED, PLACEBO-CONTROLLED PILOT STUDY IN HUNTINGTON'S DISEASE (CIT-HD)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究计划建议在20名轻度亨廷顿病(HD)成人患者中进行一项双盲、安慰剂对照的临床试验，以解决以下研究目标：1)确定西酞普兰与安慰剂在早期HD患者中对执行功能和其他结果变量的影响，包括功能测量(与健康相关的生活质量、工作效率和自我报告的注意力)、运动表现和精神状态；2)研究SSRI治疗后早期HD患者执行功能和功能状态的关系；3)检查西酞普兰治疗对容量和代谢的影响(即，最近诊断的亨廷顿病患者的新纹状体中的N-乙酰-天冬氨酸浓度)。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 20 adults with mild Huntington's Disease (HD) to address the following research aims: 1) To determine the effect of citalopram compared to placebo in patients with early HD on executive function and other outcome variables, including functional measures (health-related quality of life, work productivity, and self-reported attention), motor performance, and psychiatric status, 2) To study the relationship between executive function and functional status in patients with early HD after SSRI treatment and 3) to examine the effect of citalopram treatment on volumetric and metabolic (i.e., N-Acetyl-Aspartate concentrations) in the neostriatum among patients with recently diagnosed Huntington's Disease.